Comprehensively prognostic and immunological analysis of snail family transcriptional repressor 2 in pan-cancer and identification in pancreatic carcinoma

Background Snail family transcriptional repressor 2 (SNAI2) is a transcription factor that induces epithelial to mesenchymal transition in neoplastic epithelial cells. It is closely related to the progression of various malignancies. However, the significance of SNAI2 in human pan-cancer is still largely unknown. Methods The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and Cancer Cell Line Encyclopedia (CCLE) databases were taken to examine the SNAI2 expression pattern in tissues and cancer cells. The link between SNAI2 gene expression levels and prognosis, as well as immune cell infiltration, was investigated using the Kaplan-Meier technique and Spearman correlation analysis. We also explored the expression and distribution of SNAI2 in various tumor tissues and cells by the THPA (Human Protein Atlas) database. We further investigated the relationship between SNAI2 expression levels and immunotherapy response in various clinical immunotherapy cohorts. Finally, the immunoblot was used to quantify the SNAI2 expression levels, and the proliferative and invasive ability of pancreatic cancer cells was determined by colony formation and transwell assays. Results We discovered heterogeneity in SNAI2 expression in different tumor tissues and cancer cell lines by exploring public datasets. The genomic alteration of SNAI2 existed in most cancers. Also, SNAI2 exhibits prognosis predictive ability in various cancers. SNAI2 was significantly correlated with immune-activated hallmarks, cancer immune cell infiltrations, and immunoregulators. It’s worth noting that SNAI2 expression is significantly related to the effectiveness of clinical immunotherapy. SNAI2 expression was also found to have a high correlation with the DNA mismatch repair (MMR) genes and DNA methylation in many cancers. Finally, the knockdown of SNAI2 significantly weakened the proliferative and invasive ability of pancreatic cancer cells. Conclusion These findings suggested that SNAI2 could be used as a biomarker in human pan-cancer to detect immune infiltration and poor prognosis, which provides a new idea for cancer treatment.

[1]  A. Jemal,et al.  Cancer statistics, 2023 , 2023, CA: a cancer journal for clinicians.

[2]  Shanshan Qin,et al.  LncRNA ELF3-AS1 inhibits gastric cancer by forming a negative feedback loop with SNAI2 and regulates ELF3 mRNA stability via interacting with ILF2/ILF3 complex , 2022, Journal of Experimental & Clinical Cancer Research.

[3]  Yang Ming,et al.  Transcription factor SNAI2 exerts pro-tumorigenic effects on glioma stem cells via PHLPP2-mediated Akt pathway , 2022, Cell Death & Disease.

[4]  T. Ogihara,et al.  Slug Mediates MRP2 Expression in Non-Small Cell Lung Cancer Cells , 2022, Biomolecules.

[5]  T. Tan,et al.  Osteopontin (OPN/SPP1), a Mediator of Tumor Progression, Is Regulated by the Mesenchymal Transcription Factor Slug/SNAI2 in Colorectal Cancer (CRC) , 2022, Cells.

[6]  Q. Ouyang,et al.  Protein Disulfide-Isomerase A3 Is a Robust Prognostic Biomarker for Cancers and Predicts the Immunotherapy Response Effectively , 2022, Frontiers in Immunology.

[7]  Hua Huang,et al.  SNAI2 promotes the development of ovarian cancer through regulating ferroptosis , 2022, Bioengineered.

[8]  Eun Sug Park,et al.  SLUG is a key regulator of epithelial-mesenchymal transition in pleomorphic adenoma , 2022, Laboratory Investigation.

[9]  J. Reith,et al.  Tumor-Infiltrating Lymphocytes and Cancer Markers in Osteosarcoma: Influence on Patient Survival , 2021, Cancers.

[10]  P. Kantoff,et al.  Dynamic expression of SNAI2 in prostate cancer predicts tumor progression and drug sensitivity , 2021, Molecular oncology.

[11]  H. Seno,et al.  SNAIL2 contributes to tumorigenicity and chemotherapy resistance in pancreatic cancer by regulating IGFBP2 , 2021, Cancer science.

[12]  Wei-Lin Jin,et al.  B7-H3/CD276: An Emerging Cancer Immunotherapy , 2021, Frontiers in Immunology.

[13]  M. Humphries,et al.  A SNAI2-PEAK1-INHBA stromal axis drives progression and lapatinib resistance in HER2-positive breast cancer by supporting subpopulations of tumor cells positive for antiapoptotic and stress signaling markers , 2021, Oncogene.

[14]  F. Petrelli,et al.  Predictive role of microsatellite instability for of PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials. , 2021, ESMO open.

[15]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[16]  E. Engleman,et al.  Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. , 2020, Annual review of pathology.

[17]  Juan Lu,et al.  PD-L1 Expression is Highly Associated with Tumor-Associated Macrophage Infiltration in Nasopharyngeal Carcinoma , 2020, Cancer management and research.

[18]  M. Mendiburu-Eliçabe,et al.  Stromal SNAI2 Is Required for ERBB2 Breast Cancer Progression , 2020, Cancer Research.

[19]  Yibin Kang,et al.  ASB13 inhibits breast cancer metastasis through promoting SNAI2 degradation and relieving its transcriptional repression of YAP , 2020, Genes & development.

[20]  Fan Zhang,et al.  TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment , 2020, bioRxiv.

[21]  Tianzhi Huang,et al.  Stem cell programs in cancer initiation, progression, and therapy resistance , 2020, Theranostics.

[22]  D. Vignali,et al.  Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy , 2020, Journal for ImmunoTherapy of Cancer.

[23]  G. J. Yoshida.  Regulation of heterogeneous cancer-associated fibroblasts: the molecular pathology of activated signaling pathways , 2020, Journal of experimental & clinical cancer research : CR.

[24]  H. V. van Laarhoven,et al.  MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma. , 2020, Cancer treatment reviews.

[25]  E. Robert McDonald,et al.  Quantitative Proteomics of the Cancer Cell Line Encyclopedia , 2020, Cell.

[26]  Jieyu Wang,et al.  SNAI2 3'untranslated region promotes the invasion of ovarian cancer cells by inducing MARCKS expression , 2019, Journal of Cancer.

[27]  Zemin Zhang,et al.  GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis , 2019, Nucleic Acids Res..

[28]  C. Blanpain,et al.  EMT Transition States during Tumor Progression and Metastasis. , 2019, Trends in cell biology.

[29]  E. Hui.  Immune checkpoint inhibitors , 2019, Reactions Weekly.

[30]  F. Ghiringhelli,et al.  The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer , 2019, Cancers.

[31]  C. Brennan,et al.  Tumor mutational load predicts survival after immunotherapy across multiple cancer types , 2019, Nature Genetics.

[32]  Qian Chu,et al.  The role of neoantigen in immune checkpoint blockade therapy , 2018, Experimental Hematology & Oncology.

[33]  R. Najafi,et al.  PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy , 2018, Journal of cellular physiology.

[34]  M. Carlino,et al.  Immune Checkpoint Inhibitor Toxicity , 2018, Current Oncology Reports.

[35]  Xiaolong Wang,et al.  SREBP1, targeted by miR-18a-5p, modulates epithelial-mesenchymal transition in breast cancer via forming a co-repressor complex with Snail and HDAC1/2 , 2018, Cell Death & Differentiation.

[36]  Tim De Meyer,et al.  Analysis of DNA methylation in cancer: location revisited , 2018, Nature Reviews Clinical Oncology.

[37]  H. Ditzel,et al.  SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer , 2018, Breast Cancer Research.

[38]  J. Zenklusen,et al.  SnapShot: TCGA-Analyzed Tumors , 2018, Cell.

[39]  Jedd D. Wolchok,et al.  Cancer immunotherapy using checkpoint blockade , 2018, Science.

[40]  Jennifer R. Grandis,et al.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer , 2018, Nature Reviews Clinical Oncology.

[41]  Wei Liu,et al.  Transcriptome-derived stromal and immune scores infer clinical outcomes of patients with cancer , 2018, Oncology letters.

[42]  L. Rasmussen,et al.  DNA mismatch repair and its many roles in eukaryotic cells. , 2017, Mutation research.

[43]  A. Ribas,et al.  SnapShot: Immune Checkpoint Inhibitors. , 2017, Cancer cell.

[44]  R. Kalluri.  The biology and function of fibroblasts in cancer , 2016, Nature Reviews Cancer.

[45]  Howard Cedar,et al.  DNA Methylation in Cancer and Aging. , 2016, Cancer research.

[46]  J. Gomez-Cambronero,et al.  The transcription factors Slug (SNAI2) and Snail (SNAI1) regulate phospholipase D (PLD) promoter in opposite ways towards cancer cell invasion , 2016, Molecular oncology.

[47]  P. Campbell,et al.  Somatic mutation in cancer and normal cells , 2015, Science.

[48]  G. Kempermann.  Faculty Opinions recommendation of Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. , 2015 .

[49]  Jun S. Liu,et al.  The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans , 2015, Science.

[50]  Chuanhui Xu,et al.  HMGA2 induces transcription factor Slug expression to promote epithelial-to-mesenchymal transition and contributes to colon cancer progression. , 2014, Cancer letters.

[51]  Lourdes M. Nogueira,et al.  SNAI2 Modulates Colorectal Cancer 5-Fluorouracil Sensitivity through miR145 Repression , 2014, Molecular Cancer Therapeutics.

[52]  M. Barcellos-Hoff,et al.  The evolution of the cancer niche during multistage carcinogenesis , 2013, Nature Reviews Cancer.

[53]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[54]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[55]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[56]  Paulo A. S. Nuin,et al.  EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer , 2012, BMC Cancer.

[57]  J. Shih,et al.  The EMT regulator slug and lung carcinogenesis. , 2011, Carcinogenesis.

[58]  Buzz Baum,et al.  Transitions between epithelial and mesenchymal states in development and disease. , 2008, Seminars in cell & developmental biology.

[59]  M. Pérez-Caro,et al.  Function of the zinc-finger transcription factor SNAI2 in cancer and development. , 2007, Annual review of genetics.

[60]  Héctor Peinado,et al.  Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? , 2007, Nature Reviews Cancer.

[61]  M. Nieto,et al.  The Snail genes as inducers of cell movement and survival: implications in development and cancer , 2005, Development.

[62]  M. Nieto,et al.  The snail superfamily of zinc-finger transcription factors , 2002, Nature Reviews Molecular Cell Biology.

[63]  Michael K. Wendt,et al.  Deconstructing the mechanisms and consequences of TGF-β-induced EMT during cancer progression , 2011, Cell and Tissue Research.

[64]  Marco Ranucci,et al.  A Meta-analysis of Randomized Clinical Trials , 2008 .

[65]  Guo-Min Li,et al.  Mechanisms and functions of DNA mismatch repair , 2008, Cell Research.